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Part 1: HIV-1 Binding and Entry Events: Implications for Vaccine Strategies
Part 2: The Effects of AZT on the Relative Mutation Frequency of FIV (121 pp.)
Director: Jack H. Nunberg
Part 1:
We have examined the relationship between coreceptor utilization and
sensitivity to neutralization in a primary isolate (PI) of human immunodeficiency
virus (HIV) and its T-cell line adapted (TCLA) derivative. We determined that
adaptation of the PI virus 168P results in the loss of the unique capacity of PI
viruses to utilize the CCR5 coreceptor, and in the acquisition by the TCLA 168C
virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs).
In experiments wherein infection by 168P is directed via either the CCR5 or
CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions
bearing a molecularly cloned 168P envelope protein, remain refractory to
neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor
utilized. This study suggests that coreceptor utilization is not a primary
determinant of differential neutralization sensitivity in PI and TCLA virus.
Current recombinant HIV gp120 protein vaccine candidates fail to elicit
antibodies capable of neutralizing infectivity of primary patient isolates. Here,
novel ‘fusion-competent’ HIV vaccine immunogens are discussed that capture
the transient envelope-CD4-coreceptor structures which arise during HIV binding
and fusion. In a transgenic mouse immunization model, these formaldehydefixed whole cell vaccines elicited antibodies capable of neutralizing infectivity of
23 of 24 primary HIV isolates form diverse geographical locations and genetic
clades A-E. Development of these novel fusion-dependent immunogens may
lead to a broadly effective HIV isolates.
Part 2:
We have developed a host range system to measure the mutation frequency of
feline immunodeficiency virus (FIV), the feline homologue of HIV-1. When wildtype FIV was grown in the presence of a known mutagen, 5-bromo-2’deoxyuridine (BUdR), a dose-dependent increase of host range mutants was
detected. Using this system, we have evaluated the effects of antiviral drugs
upon the mutation frequency of FIV. Subinhibitory concentrations of 3’-azido-3’deoxythymidine (AZT), the most common antiviral drug used in AIDS
chemotherapy, increased the mutation frequency of FIV in a dose-dependent
manner. Two other antivirals, 2’,3’-dideoxyinosine (ddl) and 2 \3 ’-dideoxycytidine
(ddC) did not show this effect.
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Chapter 1
Introduction
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of
the acquired immune deficiency syndrome (AIDS) (1,2). This retrovirus has
caused a worldwide epidemic and the WHO (World Health Organization) has
estimated that 40 million people will be infected by the year 2000 (3). To date,
there is no cure for HIV infection, limited effective therapy, and no protective
vaccine. Current vaccine strategies have focused on the envelope glycoprotein
of HIV, the viral protein that mediates the early binding and entry events that
ultimately lead to infection. However, all vaccine candidates thus far have failed
to elicit antibodies capable of neutralizing infection by primary isolates (Pis), i.e.
viruses obtained from infected individuals (4-7).

Synthesis and Processing of HIV Envelope Glycoprotein
The synthesis and processing of the HIV envelope glycoprotein occurs in
the secretory pathway of the infected host cell. The envelope protein is originally
synthesized as a precursor polyprotein, which is cotranslationally transferred into
the lumen of the endoplasmic reticulum (ER). During this time, the precursor
protein is modified by cellular enzymes by adding high-mannose units to the
protein. This yields an HIV precursor glycoprotein with a molecular mass of 160
kd (gp160) (8). While in the ER lumen, intramolecular disulfide bonds are formed
to produce a folded monomer of gp160 (9), which then associates into trimeric
complexes (10). After oligomerization, the envelope complexes are
i
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transferred to the Golgi apparatus where the carbohydrate moieties are
terminally modified to produce complex/hybrid carbohydrate chains (11).
While in the Golgi apparatus, the gp160 precursors are cleaved into the
noncovalently linked gp120 and gp41 subunits, forming the mature envelope
glycoprotein (12). The cleavage is mediated by the cellular serine proteases
furin and PC7 (13-15). These proteases act on each chain of the gp160
oligomer and cleave at a highly conserved basic region that defines the Cterminus of gp120 and the N-terminus of gp41. Cleavage of the precursor
protein is thought to induce a conformational change that releases gp41 from the
C-terminus of gp120 and buries the N-terminal hydrophobic fusion peptide of
gp41 within the oligomer (16-18). After cleavage, the mature oligomers are
transported from the Golgi apparatus to the plasma membrane of the host cell
via a cellular vesicle transport system (19).

The HIV-1 Envelope Glycoprotein
HIV envelope-mediated binding and entry is the initial step in the
replication process of the virus. A series of molecular interactions between the
host cell and virus is initiated by the binding of the viral envelope glycoprotein to
the cellular CD4 molecule of CD4+ T lymphocytes and cells of the monocytemacrophage lineage (20-25). The envelope protein consists of the surface
subunit, gp120, which is noncovalently associated to the transmembrane
subunit, gp41 (26,27). The gp120/gp41 heterodimer assembles into trimeric
complexes to form the functional HIV envelope protein (11,28-31).
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The gp120 subunit of the HIV envelope glycoprotein is a highly
glycosylated, hydrophilic protein located on the surface of the virion and plasma
membrane of infected cells. HIV gp120 has 24 potential sites for N-linked
glycosylation (Asn-X-Ser/Thr), 13 of which are highly conserved among different
HIV-1 viral isolates (32,33). The amino acid sequence comparison of gp120
from HIV-1, HIV-2, and SIV isolates also reveals that there are 18 highly
conserved cysteine residues. The conservation of these amino acids suggests
that disulfide bonds are essential to the structure and function of this protein.
The secondary structure of the envelope glycoprotein and the nine putative
disulfide bonds found in gp120 are depicted in Fig. 1 (32,34).

F ic L l : The predicted folding patterns of HIV-1 envelope glycoprotein.
Hypervariable domains of gp120 are designated V1-V5. Regions of gp41 are as
follows: F, fusion peptide; TM, transmembrane domain.
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Despite the conservation of the overall secondary structure of the
envelope glycoprotein, all isolates of HIV-1, HIV-2, and SIV have extensive
sequence heterogeneity throughout the envelope gene (35). There is up to 50%
variation in the envelope amino acid sequence in HIV-1 strains, although other
parts of the genome are relatively conserved (36). The gp120 subunit contains
five variable loops, designated V1-V5, which are separated by conserved
regions. It has been previously shown that the envelope protein contains the
determinants for cell tropism, cytopathic effect, and coreceptor utilization. The
variable V3 loop has been implicated as a key player in these determinants.
Changes in the V3 loop can affect cell tropism by altering the ability of viral
isolates to grow in primary monocyte-derived macrophages and T cell lines
(5,37-42). This variable region is also a major determinant of cytopathic effects,
such as syncytium formation in primary lymphocyte cultures (43-45), and has
been implicated in differences in neutralization sensitivity of viral isolates to
soluble CD4 (sCD4) (46,47) and to V3-directed monoclonal antibodies (mAbs)
(48-50). Recently, the V3 loop has also been found to play a role in the
differential utilization of coreceptors (51-54).
The gp120 subunit is anchored to the surface of virions or infected cells
through noncovalent interaction with the transmembrane subunit, gp41. Gp41
traverses the lipid bilayer once and serves as the anchor of the envelope
glycoprotein. Mutational analysis reveals that both the N-terminus and Cterminus of gp120 mediate the noncovalent contact between gp120 and gp41
(26,42,55,56). Although, the contacts mediated by gp41 are yet to be identified,
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a disulfide loop in the N-terminus of gp41 is believed to form a knob that fits into
a pocket in the gp120 subunit (57,58).
The N-terminus of gp41 has a hydrophobic region of approximately 20
amino acids which is required for fusion of the viral and cell membrane, and is
termed the fusion peptide (26,59,60). Near the C-terminal end of gp41 resides
an additional hydrophobic domain that spans the cell or viral membrane, serving
as an anchor for the glycoprotein heterodimer (61). The domain between these
two hydrophobic regions, the ectodomain, is highly conserved. The ectodomain
is proposed to form a structure similar to a leucine zipper motif and is believed to
form a coiled-coil structure, which facilitates the insertion of the fusion peptide
into the target cell membrane upon activation (62).

CD4 and Coreceptor Binding
It has long been known that the cellular CD4 molecule is the high affinity
receptor to which the HIV envelope glycoprotein binds to initiate envelopemediated membrane fusion (22,23). However, CD4 binding alone is not
sufficient for HIV envelope-mediated fusion and infection of the host cell. When
nonhuman cells were transfected to express human CD4, HIV-1 could not
mediate envelope fusion and/or infection (24,63-65). This suggested that there
was a coreceptor involved in HIV binding and entry.
Recently, HIV-1 coreceptors, cellular molecules that act in conjunction
with the CD4 molecule to allow envelope-mediated fusion, have been elucidated
(REF). The HIV-1 coreceptors are members of the chemokine receptor family

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

6

and are seven transmembrane-segment G-protein-coupled molecules that
normally function as receptors to the a- and P-chemokines. Chemokines are
small molecules involved in the chemotactic recruitment of selected leukocytes
to sites of inflammation (66,67). With the discovery of these coreceptors has
come the understanding that various isolates of HIV-1 utilize different
coreceptors for binding and entry. The commonly used T-cell line-adapted
(TCLA) isolates utilize the CXCR4 ct-chemokine receptor exclusively (68,69),
whereas Pis of HIV-1 that are monocytropic/non-syncytium-inducing (NSI) utilize
only the P-chemokine receptor CCR5. HIV-1 Pis that are
lymphocytropic/syncytium-inducing (SI) are able to utilize either CXCR4 or CCR5
(52,70-74).

PI and TCLA Viruses
Pis of HIV are obtained by limited cultivation of patient peripheral blood
mononuclear cells or patient plasma with uninfected cells (1,75). There is a
spectrum of biological phenotypes of these PI viruses. SI isolates infect and
induce syncytia formation in peripheral blood lymphocytes (PBLs). SI isolates
can also replicate in the MT2 T-cell line, but are unable to replicate in less
permissive T-cell lines, such as H9 cells (76,77). In contrast, NSI isolates are
only able to replicate in primary cells, and unlike the SI isolates, are able to
replicate in primary monocyte-derived macrophages (78). Transitional
intermediates of these two biological phenotypes of the primary isolates have
been detected in vivo (79). During active infection, NSI isolates predominate
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during the early/asymptomatic stage while SI isolates slowly arise from the NSI
population (79,80). The emergence of SI isolates during infection is associated
with progression to AIDS (80). The spectrum of the biological phenotypes can
also be extended to TCLA isolates (46), and the variation of these phenotypes
may reflect the continuum of the multiple interactions between the virus and cell
during the early binding and entry events of infection.
PI and TCLA viruses of HIV not only differ in coreceptor utilization and cell
tropism, but also exhibit a marked difference in neutralization sensitivities. PI
viruses exhibit decreased sensitivities to in vitro neutralization by sCD4 (5,7,8183), sera from infected individuals (5,6,84,85), monoclonal antibodies (48-50),
and HIV vaccine sera (4-7).
During adaptation of PI viruses to growth in established T-cell lines, the
change in cell tropism is accompanied by changes in both neutralization
sensitivity and cytopathic effect. The current generation of vaccines comprised
of recombinant gp120 (rgp120) subunits elicits antibodies that potently neutralize
infection of homologous TCLA viruses (86-89), however PI viruses are refractory
to in vitro neutralization by the vaccine sera. The reason behind the universal
failure of rgp120 vaccine sera to neutralize PI viruses remains elusive. However,
the structural and/or functional differences between PI and TCLA viruses in the
process of binding and entry may hold some of these answers.
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s
Conformational Changes Mediated by Binding and Entry Events
During binding and entry, the HIV envelope protein undergoes a series of
complex interactions and conformational changes that result in membrane
fusion. Initially, the envelope complex binds to CD4 and undergoes a
conformational change that results in an increased exposure of certain antibody
epitopes, also known as CD4-induced (CD4i) epitopes (90-92). Monoclonal
antibodies from HIV infected individuals that are specific for the CD4i epitopes
have been isolated and been found to neutralize a range of PI and TCLA viruses
(93,94). During the binding and entry process, the dissociation (or shedding) of
the gp120 from the gp41 subunit of the envelope complex increases (95-99).
Along with conformational changes occurring in the viral envelope complex upon
CD4 binding, there also are conformational changes observed in the CD4
receptor (100,101). These changes in CD4 and envelope facilitate the
subsequent interactions with the coreceptor, forming a trimolecular complex
(53,54,102,103). The conformational changes in the envelope-CD4-coreceptor
complex mediate the exposure and activation of the gp41 fusion peptide, and
ultimately lead to the fusion of the opposed virus and cell membranes
(26,104,105).
During the process of envelope-mediated fusion, a number of neutralizing
epitopes are exposed, albeit transiently. As mentioned above, a number of
human mAbs from infected individuals recognize CD4i epitopes, and are able to
neutralize a diverse range of PI and TCLA viruses (93,94). It has also been
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shown that sera from infected individuals typically neutralize Pis with frequencies
of 30-50%, although the results vary for individual sera and individual viruses
(106-108). This indicates that there is an inherent difference in the antibodies
elicited from infected individuals as compared to the antibodies elicited from
rgp120 vaccines.

Proposed Work
The following studies explore the relationship between neutralization
sensitivity and coreceptor utilization, especially in regards to the changes that
accompany adaptation of Pis to growth in T-cell lines. We hypothesize that Pis
are refractory to neutralization as a result of the unique ability to utilize the CCR5
coreceptor, rather than CXCR4. To test this hypothesis, we examine a wellcharacterized SI primary virus, 168P, under experimental conditions where
infection is directed via the CXCR4 and CCR5 pathway to determine whether
coreceptor pathway is a determinant of neutralization sensitivity.
It has been previously shown that PI viruses are refractory to neutalization
by rgp120 vaccine sera. This vaccine strategy incorporates a static envelope as
the immunogen, i.e. an envelope that is not interacting with CD4 and coreceptor.
In an infected individual, however, the immune system is responding to an
envelope protein expressed in its native oligomeric conformation and is actively
participating in the binding and entry process. An active infection, therefore,
presents the immune system with the transient, fusion-dependent epitopes that
arise during fusion. We hypothesize that the failure of current rgp120 vaccine
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strategies is due to the fact that the fusion-dependent epitopes present during an
active infection are not incorporated into the immunogen. We test this
hypothesis by formulating a fusion-competent’ vaccine that incorporates a
functioning envelope interacting with CD4 and coreceptor into the immunogen,
and determine if this new vaccine strategy can elicit antibodies capable of
neutralizing primary isolates of HIV.
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Abstract

We have examined the relationship between coreceptor utilization and sensitivity
to neutralization in a primary (PI) isolate of HIV and its T cell line adapted (TCLA)
derivative. We determined that adaptation of the PI virus 168P results in the loss
of the unique capacity of PI viruses to utilize the CCR5 coreceptor, and in the
acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed
monoclonal antibodies (MAbs). In experiments wherein infection by 168P is
directed via either the CCR5 or CXCR4 pathway, we demonstrate that the virus,
as well as pseudotyped virions bearing a molecularly cloned 168P envelope
protein, remain refractory to neutralization by MAbs 257-D, 268-D, and 50.1
regardless of the coreceptor utilized. This study suggests that coreceptor
utilization is not a primary determinant of differential neutralization sensitivity in
PI and TCLA viruses.
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Although CD4 had long been recognized as the cellular receptor to which
the human immunodeficiency virus type 1 (HIV) envelope protein binds (9, 21,
22), it had also been recognized that expression of CD4 alone is insufficient to
render non-human cells susceptible to HIV infection (4, 5, 22). Similarly, different
HIV isolates display different abilities to infect CD4-positive human
macrophages, T lymphocytes, and established T cell lines (31, 32, 35),
suggesting that additional molecules may be responsible for cell tropism
specificity. During the past year, cellular molecules that act in conjunction with
CD4 have been identified as required cofactors for HIV envelope proteinmediated binding and entry (1, 6, 10-12, 14). These HIV coreceptors are
members of the superfamily of seven-transmembrane segment G-protein
coupled receptors and act primarily as cellular receptors for chemokines.
The discovery of cellular coreceptors for HIV has provided new
perspectives for understanding these early events in HIV infection (see review
(2)). Thus, phenotypically distinct isolates of HIV utilize as coreceptors different
chemokine receptor molecules. Although all primary isolates (PI) of HIV infect
primary T lymphocytes, some also infect cells of the macrophage lineage (31,
32). These monocytropic isolates utilize the CCR5 chemokine receptor, whose
natural ligands include the chemokines RANTES, MIP-1aand MIP-ip (1, 6, IQ12). Monocytropic isolates do not induce syncytia in primary lymphocyte culture
and do not infect established T cell lines (31). During the late course of HIV
infection, syncytium-inducing (SI) primary viruses often arise from the population
of monocytropic viruses (31, 32). These SI primary isolates no longer infect
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macrophages, and utilize both CCR5 and another chemokine receptor, CXCR4
(7, 33, 38). CXCR4, whose natural chemokine ligand is SDF-1 (3, 27), was
originally identified by Berger and colleagues as the cofactor used by laboratoryadapted viruses (14). In fact, the common laboratory viruses (lllb/LAI, LAV, RF)
are unable to utilize CCR5 coreceptor (1, 6, 10-12), presumably reflecting the
lack of CCR5 expression in most established T cell lines (1, 13). Although some
primary isolates utilize additional chemokine receptor molecules, notably CCR3
and CCR2b (6, 11, 18), the relationship between these coreceptors and viral
phenotypes is less clear. The ability to utilize CCR5 coreceptor, however, is
unique to PI viruses.
Paralleling these differences in coreceptor utilization and cell tropism are
differences in sensitivity to virus neutralization. Although laboratory-adapted
isolates of HIV can be potently neutralized by sera elicited by recombinant gp120
protein, primary isolates are largely refractory to neutralization by rgp120 vaccine
sera (23, 37). Similarly, PI viruses are significantly more resistant than TCLA
viruses to neutralization by gp120-directed monoclonal antibodies (MAbs) (25,
37) and to inhibition by soluble forms of CD4 (8). We and others have
demonstrated that neutralization sensitivity develops concomitantly with
adaptation of PI isolates to persistent growth in established T cell lines (24, 37).
By studying pedigreed PI and TCLA viruses (168P and 168C, respectively), we
have shown that adaptation renders the TCLA virus sensitive not only to rgp120
vaccine sera and CD4 immunoadhesin, but also to MAbs directed to the V3-loop
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of gp120 (37). However, the basis for this increase in neutralization sensitivity
remains unclear.
In this report, we explore the relationship between neutralization sensitivity
and coreceptor utilization, especially with regard to changes that accompany
adaptation. We examined neutralization sensitivity of the well characterized SI
primary virus 168P under experimental conditions where infection can be
directed via either the CXCR4 or CCR5 pathway. The pedigreed TCLA derivative
168C utilizes only CXCR4 and was sensitive to neutralization by the panel of V3directed MAbs used in these studies. However, the primary 168P virus remained
refractory to neutralization regardless of coreceptor pathway taken. Our findings
suggest that envelope protein structure, and not coreceptor utilization, is the
primary determinant of differential neutralization sensitivity in PI and TCLA
viruses.

Coreceptor utilization by pedigreed PI and TCLA viruses
Cross-sectional surveys of coreceptor use have shown that primary SI
isolates generally utilize CXCR4 and CCR5 coreceptors, whereas unrelated
laboratory-adapted isolates utilize only CXCR4 (1, 6, 7,10-12, 14, 33, 38). We
wished to confirm this trend in a longitudinal study of adaptation. We previously
described the adaptation of the primary SI virus 168P to persistent growth in the
FDA/H9 T cell line, and the concomitant development of neutralization sensitivity
in the resulting TCLA virus 168C (37). In the present study, the ability of these
pedigreed viruses to utilize specific coreceptors was tested by infection of U87
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human glioma cell lines expressing CD4 (U87-CD4) and the specific coreceptor
(19). Figure 1 confirms the ability of the SI 168P virus to utilize both CXCR4 and
CCR5, and the subsequent loss of this latter specificity in the 168C TCLA virus.
Infection was dependent on coreceptor expression, and both PI and TCLA
isolates could also utilize CCR3 (data not presented).
In keeping with the determined coreceptor specificity, infection could be
blocked by addition of coreceptor-specific ligands. Thus, 168P virus infection of
CCR5-expressing cells was blocked by the CCR5-specific ligands RANTES,
MIP-1a, and MIP-1{3 (1, 6, 10-12) (Figure 1). Similarly, infection of CXCR4expressing U87-CD4 cells by either virus could be blocked by the CXCR4specific chemokine ligand SDF-1 (3, 27) (data not presented).

Coreceptor pathway and neutralization sensitivity
In previous work, we demonstrated that the PI 168P virus is refractory to
neutralization by HIV MN gp120 vaccine sera and by several well-characterized
V3-directed murine MAbs which strongly neutralize infectivity of the TCLA 168C
virus (37). In the present study, we extended the panel of MAbs to include two
V3-directed human MAbs: 257-D and 268-D (17). These well-characterized
human MAbs recognize core epitopes at the crown of the V3 loop of gp120
(KRIHI and HIGPGR, respectively) - linear sequences known to be present in
both 168P and 168C envelope proteins (37). These epitope predictions were
confirmed by gp120-capture ELISA (26) which demonstrated equal binding to
envelope protein in detergent-solubilized 168P and 168C virions (data not
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presented). Sensitivity to neutralization by these human MAbs was determined in
a standard assay using phytohemagglutinin (PHA)-activated peripheral blood
lymphocytes (PBLs) (37). MAbs 257-D and 268-D were found to potently
neutralize 168C, but failed to neutralize 168P (Figure 2). This pattern of
neutralization sensitivity is similar to that previously described for the V3-directed
murine MAb 50.1 (30, 36, 37).
To examine whether sensitivity to neutralization was affected by the
coreceptor pathway utilized in infection of PBLs, we used inhibitory
concentrations of CCR5-specific chemokine ligands RANTES, MIP-1a, and MIP1P in order to restrict infection to the CXCR4 pathway. Addition of these
chemokines to the PBL cultures did not affect virus growth, nor did it affect
sensitivity to neutralization by the V3-directed human MAbs (Figure 2). To the
extent that CCR5 blockade was complete, these results suggest that the simple
availability of the CCR5 pathway is not a factor in the resistance of PI viruses to
neutralization.
To strengthen this conclusion, we examined neutralization sensitivity in
human U87-CD4 cell lines expressing only CXCR4 or CCR5. Using this method,
we confirmed that the SI 168P virus remained refractory to neutralization by
human MAbs 257-D and 268-D as well as by the murine MAb 50.1, regardless of
whether infection occurred via CXCR4 or CCR5 (Figure 3). These results
suggest that availability of the CCR5 pathway is not a primary determinant for
the resistance of PI viruses to neutralization. The TCLA 168C virus utilized
CXCR4 only and was sensitive to neutralization.
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Molecularly cloned PI and TCLA envelope genes
In order to understand better the changes that accompany adaptation,
and those that determine coreceptor utilization and neutralization sensitivity, we
molecularly cloned the envelope genes of the 168P and 168C viruses. Highfidelity XL® PCR (rTth and VentR® DNA Polymerase; PE Applied Biosystems)
and envA and envN primers (15) were used to amplify a 3.1 kb region of proviral
DNA encoding the rev and envelope genes. PCR products were isolated by
unidirectional T/A cloning in the eucaryotic expression vector pCR®3.1-Uni
(Invitrogen). Expression in pCR®3.1-Uni is driven by the CMV immediate early
promotor. Multiple clones were isolated from each virus, and transient
transfection studies in COS-7 cells confirmed the surface expression and fusion
competence of all clones tested (data not presented).
DNA sequence analysis demonstrated that all 168C molecular clones
analyzed encoded the three adaptation-associated amino acid changes
previously identified by PCR sequencing of the 168C virus population (V2:
I166R, C2:I282N, V3:G318R) (37). Two molecular clones o f each 168P and
168C envelope were subjected to complete DNA sequence analysis (GenBank
accession numbers AF035532 - AF035534). Molecular clones 168C23 and
168C60 were identical throughout the envelope gene. Molecular clones 168P5
and 168P23 differed from each other, and from the previously determined
sequence, at 4-5 positions distinct from those associated with adaptation. These
scattered changes within the primary virus quasispecies are considered
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inconsequential at the present level of analysis; the significance of the three
adaptation-associated changes is under separate investigation.
Functional analysis of these molecularly cloned envelope genes was
performed by incorporation of the molecularly cloned envelope protein into
pseudotyped HIV virions. We utilized an envelope-defective provirus derived
from the molecularly cloned NL4-3 provirus (kindly provided by I.S.Y Chen,
UCLA). The pNLthyABg/provirus (28) contains a Bgl\l-Bgl\\ deletion within the
envelope gene and a substitution of the viral nef gene with a cDNA encoding the
murine thy1.2 cell surface protein. The SV40 ori was subsequently introduced
into the plasmid to generate pSVNLthyABg/ (V. Planelles, unpublished).
Cotransfection of COS-7 cells (16, 20) with pSVNLthyABg/provirus and the
envelope expression plasmid resulted in the production of pseudotyped HIV
virions. Culture supernatants were harvested 3 days post-transfection, filtered
and used to infect U87-CD4 cell lines expressing coreceptor. Cells infected by
virions bearing the complementing envelope protein were identified by
immunostaining for murine thy1.2 or HIV proteins.
As anticipated, the molecularly cloned envelope proteins recapitulated the
coreceptor specificity of the parental virus population (legend Figure 4).
Pseudotyped virions containing 168C60 were only able to infect U87-CD4 cells
expressing CXCR4, while virions containing 168P23 envelope were able to infect
U87-CD4 cells expressing either CCR5 or CXCR4. Thus, the viral envelope
protein appears to be the major, if not sole, determinant of viral coreceptor use.
These findings also indicate that dual coreceptor use is a direct property of the
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envelope protein complex, and not a result of a mixture of distinct envelope
proteins in the SI virus population. This conclusion is corroborated by the failure
of CCR5-specific chemokine ligands to diminish 168P virus production in PBL
culture (Figure 2).
Finally, we wished to determine the neutralization sensitivity of
pseudotyped virions containing the molecularly cloned 168P23 and 168C60
envelope proteins, and to confirm that coreceptor pathway is not a primary
determinant of neutralization sensitivity. We found that infection of U87-CD4CXCR4 cells by pseudotyped virions containing 168C60 envelope protein was
sensitive to neutralization by MAbs 257-D, 268-D, and 50.1 at concentrations
comparable to those determined using 168C virus (Figure 4). Pseudotyped
virions containing 168P23 envelope protein remained refractory to neutralization
by all three V3-directed MAbs, regardless of the coreceptor expressed by the
U87-CD4 cell line.
In summary, we examined the relationship between coreceptor utilization
and sensitivity to neutralization by V3-directed MAbs. The observed dichotomy in
the sensitivity to neutralization of PI and TCLA viruses had suggested a discrete
difference between these viruses, and we tested one hypothesis - that PI viruses
are refractory to neutralization as a result of their unique ability to utilize the
CCR5 coreceptor, rather than CXCR4. We examined neutralization sensitivity of
a well-characterized SI primary isolate under experimental conditions wherein
the virus was forced to utilize either CCR5 or CXCR4 for infection. We showed
that coreceptor pathway is not a direct determinant of neutralization sensitivity.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

38

The primary virus envelope protein remained refractory to neutralization by V3directed MAbs regardless of the coreceptor pathway utilized. Similarly,
coreceptor utilization did not affect neutralization sensitivity by soluble CD4 (34)
or HIVIG (data not presented).
In discarding the otherwise attractive hypothesis that PI viruses escape
neutralization through their unique ability to utilize CCR5, we are left to consider
the as-yet undefined structural differences between the envelope protein
complex of PI and TCLA viruses. Several studies have suggested that critical
determinants in the envelope protein of PI viruses are less accessible than those
of TCLA viruses and that it is this differential access that determines
neutralization sensitivity (reviewed in 25). By contrast, our studies have
indicated similar binding of V3-directed MAbs to PBLs infected with
neutralization-resistant 168P or neutralization-sensitive 168C viruses (37). Thus
the basis for the differential neutralization sensitivity of PI and TCLA viruses
remains unresolved.
Our present studies also do not address whether changes in coreceptor
utilization and/or neutralization sensitivity are necessarily linked as a
consequence of adaptation. The analysis of independently-derived PI and TCLA
viruses may allow further separation of these viral phenotypes. Subsequent
dissection of the amino acid changes that distinguish pedigreed PI and TCLA
envelope proteins will help to define the structural bases underlying the changes
that accompany adaptation.
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Figure Legends
Figure 1: Coreceptor utilization by pedigreed PI and TCLA 168 viruses. U87CD4 cell lines expressing CXCR4 (■) or CCR5 ( ) were used to define the ability
of 168P and 168C viruses to utilize the respective coreceptor. CCR5 utilization
was further tested by the addition to U87-CD4-CCR5 cells of CCR5-specific
chemokines (RANTES, MIP-1a, and MIP-1P; R&D Systems) (□ ). Virus stocks
were prepared from cell culture supernatants of PBLs (168P) or FDA/H9 cells
(168C) and standardized to yield a submaximal number of foci of infection on
U87-CD4-CXCR4 cells (approx 100-200 foci/96 well microplate culture). CCR5specific chemokines (500 ng/ml each) were added to cells 1 hr prior to infection.
After 2 days of incubation, cell monolayers were fixed with methanokacetone and
immunochemically stained using HIVIG (29), anti-human ABC kit (Biomeda
Corp), and DAB substrate. * no foci were observed.

Figure 2: Neutralization sensitivity of 168 viruses in PBL culture. Virus
neutralization assays in PHA-stimulated PBL culture were performed as
previously described (37). 168P (O ,#) and 168C (□ ,■ ) virus stocks were
standardized to yield submaximal extents of virus spread during the 5 day
infection. CCR5-specific chemokines ( • ,■ ) were added as described in Figure 1.
The V3-directed MAbs are indicated. p24 antigen was determined using p24
antigen capture ELISA (SAIC Frederick) and was normalized to infected cell
control values (168P -190 ng/ml, 170 ng/ml with chemokines; 168C - 36 ng/ml,
33 ng/ml with chemokines).
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Figure 3: Neutralization sensitivity of 168 viruses in U87-CD4 cell lines
expressing CCR5 or CXCR4 coreceptor. 168P (O .*) and 168C (■) viruses were
used to infect U87-CD4 cell lines expressing CXCR4 (•.■ ) or CCR5 (O) as
described in Figure 1. The V3-directed MAbs were incubated with virus for 1 hr
prior to infection.

Figure 4: Neutralization sensitivity of pseudotyped virions in U87-CD4 cell lines
expressing CCR5 or CXCR4 coreceptor. Pseudotyped virions were derived by
cotransfection of COS-7 cells with pSVNLthyABg/ provirus and plasmid
expressing 168P23 (O ,*) or 168C60 (■) envelope protein. Virion preparations
were incubated with U87-CD4 cell lines expressing CXCR4 (•,■ ) or CCR5 (O)
as described in Figure 1; V3-directed MAbs were added as indicated. The
number of foci was normalized to control values (60-100 foci/well using U87CD4-CXCR4 cells; 10 foci/well using U87-CD4-CCR5 cells). *, no foci were
observed.
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Abstract
Current recombinant HIV gp120 protein vaccine candidates fail to elicit
antibodies capable of neutralizing infectivity of primary patient isolates. Here,
novel ‘fusion-competent’ HIV vaccine immunogens are discussed that capture
the transient envelope-CD4-coreceptor structures which arise during HIV binding
and fusion. In a transgenic mouse immunization model, these formaldehydefixed whole cell vaccines elicited antibodies capable of neutralizing infectivity of
23 of 24 primary HIV isolates from diverse geographic locations and genetic
clades A-E. Development of these novel fusion-dependent immunogens may
lead to a broadly effective HIV vaccine.
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The expanding epidemic of HIV infection threatens to engulf more than 40
million persons worldwide by the year 2000 (1). The need for an effective HIV
vaccine is urgent, but progress towards this goal has been slowed in part by the
inability of any vaccine candidate to elicit antibodies capable of neutralizing
infectivity of primary HIV isolates (Pis) from infected individuals (2). Because the
HIV envelope protein mediates the early binding and entry steps in infection,
many vaccine strategies have focused on this target. In 1993, two recombinant
forms of the surface gp120 subunit of the HIV envelope protein (rgp120) were
advanced as candidate vaccines for a large scale efficacy study sponsored by
the National Institutes of Health (NIH). These rgp120 vaccines had been shown
in clinical studies to be safe and to elicit antibodies capable of potently
neutralizing related laboratory-adapted isolates of HIV (3). Progress was stalled,
however, by findings that PI viruses, in contrast to their laboratory-adapted
derivatives, were entirely refractory to neutralization by rgp120 vaccine sera (4).
Although we now appreciate that laboratory-adapted isolates grown extensively
in established T-cell lines differ in neutralization sensitivity from primary isolates
taken from infected persons and subjected to limited growth in primary T
lymphocytes, the basis for this difference remains unclear (5). More importantly,
however, no HIV vaccine candidate has been shown to elicit potent and broad
neutralization of biologically relevant primary isolates of HIV.
In contrast to antibodies elicited by rgp120 vaccines, antibodies from
persons actively infected with HIV are able to neutralize infectivity of PI viruses,
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albeit incompletely (6). Surveys of patient sera typically report low-level
neutralization of 30-50% of primary isolates, although breadth and titers vary.
We speculated that this ability to neutralize PI viruses might be related to the
presentation of functioning envelope protein in active infection, as compared to
the static, non-functioning presentation of the envelope protein in rgp120
vaccines.
It has long been known that the oligomeric envelope protein complex
binds the cell surface CD4 molecule (7). However, with the recent discovery of
HIV coreceptors (8) has come a new vision of the dynamics of HIV envelope
protein function. We now recognize that the HIV envelope protein orchestrates a
complex series of protein-protein interactions and structural changes that
ultimately results in fusion of the virus and cell membranes, and infection of the
cell. Upon binding to CD4, the envelope protein undergoes conformational
change that facilitates subsequent interaction with one of several coreceptor
molecules (9). These 7-transmembrane domain G-protein-coupled cellular
proteins normally function as receptors for chemokines, small proteins that
mediate a variety of cell-cell interactions including those in inflammation. HIV
utilizes these coreceptors as necessary components for membrane fusion. In
general, non-syncytium-inducing (NSI)/monocytropic PI viruses use the CC
chemokine receptor 5 (CCR5), whereas SI/T-lymphocytropic PI viruses use both
CCR5 and the CXC chemokine receptor 4 (CXCR4). Interaction with either
coreceptor induces further conformational change in the envelope protein and
exposure of the hydrophobic fusion domain of the transmembrane gp41 subunit,
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which then mediates fusion of the apposed cell and virus membranes (10). On
the basis of this dynamic model of HIV binding and entry, we undertook to
develop HIV vaccine immunogens that explicitly incorporate these functional
intermediate structures.
One measure of envelope protein function is the ability to mediate cell-cell
fusion. When cells expressing envelope protein are cocultured with cells
expressing CD4 and coreceptor, multinucleated syncytia form over the course of
6-24 hr (Fig 1). For our vaccine studies, we asked whether this process of
binding and fusion might be captured in progress by formaldehyde-crosslinking
prior to extensive syncytium-formation. In these studies, the functioning envelope
protein was derived from a T-lymphocytropic PI virus obtained from the
Amsterdam Cohort (ACH168.10; 168P) (11). The molecularly cloned envelope
protein, as well as the parental SI virus, utilizes both CCR5 and CXCR4
coreceptors. COS-7 cells were transfected to express the envelope protein
(COS-env) and subsequently cocultured with human U87 glioma cells that
express CD4 and CCR5 coreceptor (U87-CD4-CCR5) (12). To capture
transitional intermediates during the process of binding and fusion, cocultures
were fixed in 0.2% formaldehyde after 5 hrs (13) when few if any multinucleate
cells were evident (Fig 1). This inactivated whole cell preparation is the ‘fusioncompetent’ immunogen.
In order to meaningfully test the ability of these complex immunogens to
elicit neutralizing antibodies, it was necessary to restrict the immune response to
viral and virus-induced epitopes. Otherwise, antibodies to CD4 and CCR5 would
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be generated that would themselves block infectivity. Therefore, it was essential
to use an animal model that was immunologically tolerant to the human (hu) CD4
and CCR5 components of the vaccine, as would also be the case in human
immunization. Thus, immunogenicity studies were performed using transgenic
mice that express hu CD4 and hu CCR5 coreceptor.
These transgenic mice were originally developed as a potential small
animal model for HIV infection (14). Expression of hu CD4 is regulated by a
murine enhancer linked to a human CD4 minigene and is active in thymocytes, T
helper lymphocytes, and monocyte lineage cells. Expression of the hu CCR5
cDNA is under the control of a murine CD4
expression cassette and is active in thymocytes and T helper lymphocytes.
Although post-entry blocks to HIV replication have to date limited the utility of this
transgenic model in infectivity studies, these animals were expected to be
immunologically tolerant to the expressed human transgenes. Mice expressing
all three relevant markers (hu CD4, hu CCR5, and mouse CD4) were used in the
immunogenicity studies reported here (15). Formaldehyde-fixed immunogens
were formulated with Ribi Adjuvant and mice were immunized subcutaneously at
3 week intervals (16).
In pilot studies, mice were immunized with either ‘fusion-competent’
immunogen or with cell controls (U87-CD4-CCR5 cells, alone or cocultured with
mock-transfected COS cells). Sensitivity of the homologous 168P virus to
neutralization by vaccine sera was determined using U87-CD4 cells expressing
either CCR5 or CXCR4 coreceptor (17). No inhibition of infectivity was observed
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in sera from mice immunized with cell controls, suggesting that the transgenic
mice were in fact tolerant to hu CD4 and CCR5 and that other adventitious
cellular reactivities did not interfere with the virus infectivity assay (Fig 2A).
More importantly, however, sera from mice immunized with ‘fusioncompetent’ immunogens were able to neutralize the homologous 168P PI virus.
Additional studies demonstrated that this neutralization activity was antibodymediated and could be adsorbed to, and subsequently eluted from, a solid
support containing Protein-A and Protein-G (18). In our experience,
neutralization of this PI virus by vaccine antiserum was unprecedented.
Furthermore, neutralization of the 168P virus by ‘fusion-competent’ serum
was observed regardless of the coreceptor used in the U87-CD4 cell infection
assay (Fig 2A). Several reports have demonstrated that in general neutralization
sensitivity is independent of specific coreceptor use (19). The fact that
neutralization is observed in this study using CXCR4, a coreceptor to which the
animal had not been exposed, argues that neutralization does not directly target
the CCR5 component of the vaccine.
To explore the role of fusion-dependent determinants in the induction of
PI virus neutralization, we expanded our studies to include ‘fusion-incompetent’
immunogens - cocultures that do not undergo cell-cell fusion. ‘Fusionincompetent’ immunogens tested include: COS-env cocultured with U87 cells (no
CD4 or CCR5 coreceptor), COS-env cocultured with U87-CD4 cells, and COSenv cells to which soluble CD4 (sCD4) was complexed (20). These immunogens
were fixed with formaldehyde and harvested (12, 13). An additional ‘fusion-
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incompetent’ immunogen comprised COS-env and U87-CD4-CCR5 cells that
were separately fixed with formaldehyde prior to mixing during the formulation of
the vaccine. Results from neutralization studies of ‘fusion-competent’ and ‘fusion-incompetent’ vaccine sera are summarized in Fig 2B.

.

In marked contrast to ‘fusion-competent’ immunogens, all ‘fusionincompetent’ immunogens were unable to elicit significant neutralization of the
homologous PI virus. These results are consistent with the well-documented
failure of rgp120 vaccines to elicit PI virus neutralization. The striking distinction
in neutralization by ‘fusion-competent’ and ‘fusion-incompetent’ vaccine sera was
also observed in assays utilizing human primary blood lymphocytes (PBLs) (Fig
3).
As with conventional rgp120 vaccines, ‘fusion-incompetent’ vaccines were
able to elicit neutralization of a related laboratory-adapted isolate, in this case the
T-cell line adapted derivative of 168P, 168C (21) (Fig 4). Neutralization titers of
the TCLA 168C virus were comparable among ‘fusion-competent’ or ‘fusionincompetent’ vaccine sera, suggesting a similar degree of inherent
immunogenicity among the vaccines.
The failure of ‘fusion-incompetent’ vaccines to elicit PI virus neutralization
in the transgenic mouse model highlights the specificity of the neutralization
elicited by ‘fusion-competent’ vaccines (22). Furthermore, the consistent failure
of ‘fusion-incompetent’ vaccine sera to inhibit PI virus infectivity argues strongly
that the immune response is not directed to adventitious human cellular targets,
such as those that confounded early studies of inactivated SIV vaccines (23).
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Rather, we suggest that ‘fusion-competent’ immunogens present unique fusiondependent determinants that mediate neutralization of PI viruses.
Although the potent neutralization demonstrated against the homologous
PI virus is unprecedented in HIV vaccine experience, it is understood that the
‘homologous’ virus will never be encountered in nature. HIV is an enormously
variable virus that exists as a swarm of related, rapidly-evolving genotypes that
cluster into phylogenetically-defined clades (24). Thus, a critical issue in HIV
vaccine development centers on the ability of vaccine antisera to neutralize a
broad range of diverse PI viruses.
To determine the breadth of PI virus neutralization elicited by ‘fusioncompetent’ immunogens, we examined the sensitivity of a panel of
representative PI viruses from five prevalent and geographically-diverse genetic
clades (25). As depicted in Fig 5, ‘fusion-competent’ sera elicited by a functioning
clade B envelope protein were able to neutralize 23 of 24 PI viruses tested monocytropic/NSI and T-lymphocytropic/SI viruses from North America/Europe
(clade B), Africa (clades A and D), Thailand (clades B and E), and India (clade
C). Despite the sequence diversity among these isolates, most were similarly
sensitive to neutralization by ‘fusion-competent’ vaccine sera. One clade A
isolate 92RW008 failed to attain >50% neutralization; this exception to the
otherwise broad pattern of neutralization further argues that ‘fusion-competent’
immunogens target primarily viral, rather than cellular, determinants. ‘Fusionincompetent’ sera were uniformly unable to neutralize these heterologous PI
viruses, in keeping with the historic failure of rgp120 immunogens. The broad
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and uniform neutralization of diverse PI viruses suggests that the critical
determinants presented by fusion-competent’ immunogens are highly
conserved, and may be intimately tied to the basic functioning of the envelope
protein in binding and fusion.
We then sought to define the molecular target for PI virus neutralization
by ‘fusion-competent’ vaccines. We had shown that the elicitation of PI virusneutralizing antibodies required as immunogen a functional envelope-CD4-CCR5
interaction. Nonetheless, these neutralizing antibodies might recognize native,
non-functioning envelope protein as antigen. A similar instance has been
reported for monoclonal antibody (mAb) 17b (26) which targets a CD4-induced
epitope on the gp120-CD4 complex but which also binds isolated gp120.
Alternatively, another gp120-CD4 specific mAb CG10 (27) does not recognize
isolated gp120 or CD4. Thus, we tested whether neutralizing antibodies could be
removed from ‘fusion-competent’ vaccine sera on incubation with envelope
protein complex expressed on the surface of transfected COS cells.
Formaldehyde-fixed COS cells expressing 168P envelope protein were
incubated with ‘fusion-competent’ serum and the recovered serum was then
tested for PI virus neutralization (28). Neutralization activity in ‘fusion-competent’
vaccine serum was removed by incubation with envelope-expressing cells, but
only minimally reduced by incubation with COS cell controls (Fig 6). Although the
static form of the envelope protein does not function as an effective immunogen,
we found that the critical fusion-dependent epitopes are sufficiently represented
on the static protein to allow binding. These data argue that PI virus neutralizing
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antibodies target, at least in part, the HIV envelope protein. Studies in progress
will define the role of specific envelope protein sequences in binding, as well as
the possible contribution of virus-induced CD4 or CCR5 determinants.
Importantly, these data also provide independent support to our argument that
neutralizing antibodies do not target adventitious cellular targets; any such .
targets would be equally recognized (or not recognized) on control COS cells.
Further delineation of the critical PI virus neutralizing determinant(s)
captured by ‘fusion-competent’ immunogens will be facilitated by the
development of PI virus neutralizing mAbs to ‘fusion-competent’ immunogens.
Based on the requirement for interaction with coreceptor, we speculate that
neutralization may target a late event in virus binding and entry. Upon binding to
coreceptor, the envelope protein must mediate fusion of the viral and cell
membranes. Cryptic but highly conserved determinants may be exposed during
this process. One possible target for neutralization might involve the triple
stranded coiled-coil structure that mediates membrane fusion and is highly
conserved among Orthomyxoviridae (Influenza), Filoviridae (Ebola), and
Retroviridae (HIV) as well as in fusion of cellular membranes (29). The fusionactive structure of the HIV envelope protein is believed to form subsequent to
CD4 and coreceptor binding by the collapse of two helical coils within each gp41
monomer to form the trimeric coiled-coil core. This structure is thought to drive
membrane insertion of the hydrophobic fusion domain of gp41 and to initiate
membrane fusion. Synthetic peptides that comprise either of the gp41 helical
coils are able to bind the cognate helical region and broadly inhibit viral infectivity
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(30). We speculate that broadly-neutralizing antibodies to ‘fusion-competent’
immunogens may likewise target structures involved in the activation of fusion.
The potency and breadth of neutralization by ‘fusion-competent’
immunogens appears to surpass that observed in sera from infected individuals.
Perhaps formaldehyde-fixation traps critical fusion-dependent structures that are
only transiently presented during active infection. It remains to be determined
whether ‘fusion-competent’ immunogens target the same neutralizing
determinants as active infection.
The ability of antibodies induced by ‘fusion-competent’ immunogens to
neutralize a broad range of PI viruses necessitates a shift in our thinking of HIV
vaccines. Whereas previous discussions regarding the possible number of HIV
serotypes were moot in the absence of any vaccine-induced neutralization, it had
been widely accepted that multiple envelope protein immunogens might be
needed to span the range of HIV sequence diversity. We now show that an
appropriately-presented clade B envelope protein can elicit potent neutralization
against most PI viruses, from multiple HIV clades. We show that not only is PI
virus neutralization achievable, we suggest that broad vaccine protection may
not require an unlimited number HIV serotypes.
Although the immunological basis for HIV vaccine efficacy is presently
unknown and controversial, there is ample reason to believe that pre-existing
neutralizing antibody may offer protection against infection and/or disease.
Passively administered neutralizing antibodies can exert potent antiviral effects
in several experimental models of HIV infection, as manifested by complete or
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partial protection (31). Antibody-mediated protection is, of course, well-accepted
in other viral infections and vaccines (32). With the ability to elicit potent HIV
neutralization will come the opportunity to determine the role of pre-existing
neutralizing antibody in HIV prophylaxis. Concerns regarding the diversity of HIV
populations are lessened by the breadth of neutralization elicited by ‘fusioncompetent’ immunogens. Still, one may raise the concern that antibodies in HIVinfected persons do not protect against disease progression. Whether the
ultimate disease course is modified by the ongoing antibody response is difficult
to assess. In any case, an established chronic infection presents special
challenges in terms of host competence and virus load and diversity, challenges
that are distinct from those envisioned in prophylactic immunization. The effect of
pre-existing antibodies in exposure to a minimal infectious dose of virus in an
immunocompetent host remains to be determined in preclinical and clinical
studies.
We recognize that in its current form an inactivated whole cell ‘fusioncompetent’ vaccine is not practical for clinical development. Nonetheless, ‘fusioncompetent’ formulations that incorporate critical fusion-dependent determinants
of PI virus neutralization can be envisioned. For example, recombinant viral
vectors that respectively express envelope and CD4 with coreceptor could be
coadministered to drive critical fusion events in vivo. Alternatively, purified fusionactive complexes could be developed as an inactivated subunit vaccine. This
novel concept of ‘fusion-competent’ immunogens may also be applicable to other
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enveloped viruses where protection has been difficult to generate other than by
live attenuated virus immunization.
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Figure Legends

Figure 1. Cell-cell fusion in cocultures of COS-env and U87-CD4-CCR5 cells
(12). Both fields are at 200x magnification.

Figure 2. Neutralization of the homologous 168P PI virus by ‘fusion-competent’
and fusion-incompetent’ vaccine sera. (A) Transgenic mice (hu CD4+, hu
CCR5+, mouse CD4+) in Studies 1-3 were immunized with ‘fusion-competent’
immunogen (COS-env with U87-CD4-CCR5) (■, □ ; n = 3 mice) or with cell
controls (U87-CD4-CCR5 cells alone or cocultured with mock-transfected COS
cells) ( • , D; n = 3 mice). Unimmunized mice were also used (A , A; n = 2 mice).
Sera were tested for neutralization of 168P using U87-CD4 cells expressing
either CXCR4 (■,•,▲ ) or CCR5 (0 ,0 , A).

Data represent averages of 3-6

neutralization assays using serum obtained 2 weeks following second and third
immunization. (B) Transgenic mice in Study 4 were immunized with ‘fusioncompetent’ immunogen (■, n = 4), ‘fusion-incompetent’ immunogens (COS-env
with U87 cells,

n = 4; COS-env with U87-CD4 cells,

n = 3; COS-env with

sCD4, o n = 2; COS-env with U87-CD4-CCR5 cells, each fixed separately prior to

mixing for immunization,

n = 2). Mock-transfected cell controls (O; n = 2) and

unimmunized mice (A; n = 2) were also used. Neutralization was independent of
specific coreceptor use (Fig 1A) and data here represent averages of 3-6
neutralization assays in U87-CD4-CXCR4 or -CCR5 cells. In some cases
individual animals were pooled to conserve serum.
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Figure 3. Neutralization of the homologous 168P PI virus in human PBL culture
Lymphocytes were isolated, stimulated with phytohemagglutinin, and grown in
the presence of interleukin-2; neutralization was determined as.described (17).
HIV p24 antigen was determined after 5 days of culture by ELISA (Coulter
Corporation). Vaccine groups are as defined in Fig 2B, and sera from individual
animals were pooled for this assay.

Figure 4. Neutralization of TCLA 168C virus by ‘fusion-incompetent’ vaccine
sera. Neutralization sensitivity of the 168P PI virus and its TCLA derivative 168C
were tested in U87-CD4-CXCR4 cells. Vaccine groups and symbols are as
defined in Fig 2B; sera from individual animals were pooled for this assay.

Figure 5. Neutralization of diverse PI viruses from clades A-E. Primary isolates
were expanded in human PBLs and neutralization was determined in permissive
U87-CD4-CCR5 (or -CXCR4) cells. Viral biotype is indicated if known. Vaccine
groups and symbols are as defined in Fig 2B; sera from individual animals were
pooled for this assay.

Figure 6. Adsorption of PI virus neutralization activity by formaldehyde-fixed
COS-env cells. ‘Fusion-competent’ vaccine serum (■) was repeatedly incubated
with formaldehyde-fixed COS-env ( ) or control COS (□) cells and tested for
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residual neutralization of 168P using U87-CD4-CXCR4 cells (27). Prebleed
serum was similarly adsorbed ( • , .3 . respectively).
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Chapter 4
Discussion
The HIV envelope protein initiates a series of complex protein-protein
interactions that ultimately lead to the fusion of the virus and cell membranes.
This process of envelope-mediated fusion has lead to the vision of a protein that
undergoes a series of complex conformational changes that expose potential
neutralizing epitopes that are conserved throughout the different clades of HIV.
We have developed a vaccine strategy that incorporates these fusion-dependent
epitopes of the functioning envelope into the immunogen, in contrast to the
current vaccine candidates which are composed of a static, nonfunctioning
envelope. We propose that it is the incorporation of the functioning envelope
interacting with CD4 and coreceptor that has made this vaccine strategy
successful in eliciting antibodies capable of neutralizing Pis of HIV in vitro.
There are numerous studies that will stem from this project. First and
foremost, spleens from the ‘fusion-compenent’ vaccinated mice will be harvested
to produce hybridomas for monoclonal antibody production. These monoclonal
antibodies will be essential for the elucidation of the epitope(s) responsible for
the production of neutralizing antibodies within this vaccine. Interestingly, it has
recently been shown that a peptide (DP-178) corresponding to the helical regions
of the gp41 core (the coiled-coiled core that consists of the leucine zipper motif)
is a potent inhibitor of HIV infection (1-4). This peptide is able to bind to the
envelope protein and inhibit conformational changes that are necessary for
envelope-mediated fusion (4-6). It was found that this peptide is
86
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only able to bind to the envelope complex and inhibit fusion after it interacts with
the cellular receptors, suggesting the coiled-coil domain of gp41 may become
accessible during the fusion process (7). It could be hypothesized that this
region is transiently accessible during binding and entry events and could be a
potential epitope for neutralization. Future studies include evaluation of our .
vaccine sera to determine if the neutralizing antibodies target this region of gp41,
as well as define other epitopes present in both gp41 and/or gp120 responsible
for eliciting neutralizing antibodies of PI viruses.
It is recognized that the current form of the inactivated whole cell ‘fusioncompetent’ vaccine is not practical for clinical development. Therefore, vaccine
strategies incorporating the critical fusion-dependent determinants of
neutralization will be developed. One approach being taken is to utilize
recombinant viral vectors (e.g. vaccinia) that would respectively express
envelope and CD4 with coreceptor. These recombinant vectors would then be
coadministered to drive the fusion events in vivo. An additional approach to be
pursued is to purify the fusion-active complexes comprised of envelope, CD4,
and coreceptor, and incorporate these complexes into an inactivated subunit
vaccine. The development of these vaccine strategies to elicit neutralizing
antibodies to PI viruses will hopefully lead to a pratical formulation of the ‘fusioncompetent’ vaccine for application in humans.
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Part 2
Chapter 5
General Introduction
Feline immunodeficiency virus (FIV) is a lentivirus that causes a natural
immunosuppressive disease in cats that is very similar to AIDS in humans (1-4).
FIV is similar to HIV-1 not only in disease progression, but also in sensitivities to
many of the antiviral drugs used in AIDS chemotherapy and in its ability to
develop resistance to these drugs. In the past, the FIV model system had been
developed to study the phenomenon of drug resistance (5-7). However, it has
now been expanded to evaluate the mutation frequency of the virus and how it is
affected by antiviral therapy.
Antiviral agents usually target a viral component that is required for
replication, such as a receptor needed for entry or an enzyme that is essential to
the replication of the viral genome. One such target is the viral RNA-directed
DNA polymerase, or reverse transcriptase (RT) of retroviruses. This enzyme is
required for the synthesis of a double-stranded DNA copy of the single-stranded
RNA viral genome. A number of reverse transcriptase inhibitors have been
approved and used for AIDS chemotherapy, including 3’-azido-3’-deoxythymidine
(AZT), 2’,3’-dideoxycytidine (ddC), 2’,3'-dideoxyinosine (ddl), and 2’-deoxy-3’thiacytidine (3TC).
The RT of FIV has been shown to be similar to HIV-1 RT in physical
properties, catalytic activities, and sensitivities to several important antiviral

89
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nucleosides (9-12). Both of these enzymes have similar Mg** requirements and
similar template specificities. The sensitivities to various RT inhibitors are also
very comparable. The competitive inhibitors 2 \3 ’-dideoxythymidine 5’triphosphate (ddTTP), 2 \3 ’-dideoxycytidine 5’-triphosphate (ddCTP), 3’-fluoro-3’deoxthymidine 5’-triphosphate (3-F-dTTP), 2’,3,-dideoxy-2’,3’didehydrothymidine 5’-triphosphate (d4TTP), and 3’-amino-3’-deoxythymidine
5’-triphosphate (3’-NH2-dTTP) were determined to have similar inhibition
constants for both HIV-1 and FIV RT. This also held true for phosphonoformate
(PFA) and phosphonoacetate (PAA), two noncompetitive inhibitors of RT (9,11).
In addition, it has been found that the FIV RT has a low fidelilty, similar to that
described of HIV-1 RT (Garvey et al., unpublished observations). These
features have made the FIV model highly relevant to HIV.
The RT inhibitor AZT is a nucleoside analogue that has been found to
have potent antiviral activity against HIV-1, and was the first nucleoside analogue
to be approved for use in AIDS chemotherapy (12). AZT requires activation by
cellular enzymes to its active form, AZT triphosphate (AZl IP). This activated
form is a dTTP analogue and competes with the natural substrate in the cell,
dTTP, for incorporation into the growing chain of DNA by RT. Once AZT has
been incorporated, the 3-azido group blocks the formation of the 3’,5’phosphodiester bond that is necessary for chain elongation, hence, DNA
synthesis is terminated. (12). This drug is widely used for treatment of HIV
infection.
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The following study utilizes the FIV system to evaluate the mutation
frequency of this retrovirus. The high mutation rate of HIV is believed to be a
critical factor in the ability of the virus to evade the immune system (13). It also
may contribute to the emergence of drug-resistant variants seen in patients
undergoing antiviral chemotherapy (13-15). Therefore, it is important to evaluate
the effect antiviral drugs have on the mutation frequency of the virus during
chemotherapy.
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Summary
We have developed a host range system to measure the mutation frequency of
feline immunodeficiency virus (FIV), the feline homologue of human
immunodeficiency virus type 1 (HIV-1). When wild-type FIV was grown in the
presence of a known mutagen, 5-bromo-2’-deoxyuridine (BUdR), a dosedependent increase of host range mutants was detected. Using this system, we
have evaluated the effects of antiviral drugs upon the mutation frequency of FIV.
Subinhibitory concentrations of 3’-azido-3’-deoxythymidine (AZT), the most
common antiviral drug used in AIDS chemotherapy, increased the mutation
frequency of FIV in a dose-dependent manner. Two other antivirals, 2’,3’dideoxyinosine (ddl) and 2’,3’-dideoxycytidine (ddC) did not show this effect.
Key words: Antiviral drugs-Feline immunodeficiency virus-Lentivirus mutation
frequency.
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Introduction
The high mutation frequency of human immunodeficiency virus type 1 (HIV-1) (13) is a major barrier to development of vaccines and chemotherapy and may also
be important in the pathogenesis of the acquired immune deficiency syndrome
(AIDS) (4). The high misincorporation rate of HIV-1 reverse transcriptase (RT),
estimated to be 2.5-5 x 1CT4 with either DNA or RNA templates, is believed to
play a major role in this. RT infidelity would result in five to ten errors each time
the genome is replicated (2,3), although the actual mutation rates may be
substantially lower than would be predicted by fidelity of RT in vitro (5). This high
variability is believed to be a critical factor in the ability of the virus to evade the
immune system, and it is a substantial limitation to development of a vaccine (4).
The high mutation frequency of HIV-1 may also contribute to the emergence of
drug-resistant variants, a serious problem faced in the treatment of AIDS
patients (4,6,7). High variability is also seen from the genotypic differences
between HIV-1 isolates obtained from AIDS patients versus the isolates obtained
early after infection. It has been suggested that the accumulation of mutations
affecting tropism, replication rates, and so on may contribute to the pathogenesis
of AIDS (4,8,9). Since the high mutation frequency of the virus appears to be
important in terms of pathogenesis and therapy, the effects of antiviral drugs
upon mutation frequency need to be considered. Therefore, we have developed
a system to evaluate the effects of antiviral drugs on mutation frequency of a
lentivirus, and we report here that the most widely used anti-HIV-1 drug, 3-azido-
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3’-deoxythymidine (AZT), increases the mutation frequency of feline
immunodeficiency virus (FIV).
Although the high error rate of HIV-1 RT is well documented, assessment
of the mutation rate at the level of virus replication has been difficult. Point
mutation rates of a murine retrovirus, murine leukemia virus, have been
determined (10), as have the mutation rates of the spleen necrosis virus
containing a reporter gene (11). However, no data are available on mutation
rates or frequencies using endogenous genes of a replicating virus, and no data
are available for a lentivirus.
Our main interest in lentivirus mutation frequencies is in the rate of
emergence of drug-resistant variants. We have previously developed a model
system using FIV for studies of resistance to AZT and other antiviral drugs (1214). With this system, we reported the first in vitro selected AZT-resistant
mutants (12), which are phenotypically similar to the AZT-resistant clinical
isolates of HIV-1 reported by Larder et al. (15,16). FIV is a lentivirus that causes
an immune deficiency in domestic cats that is clinically similar to human AIDS
(17-20), and this immunosuppressive disease can be induced experimentally in
specific-pathogen-free cats(21,22). We have shown that the purified FIV RT is
similar to the HIV-1 RT in physical properties, catalytic activities, and sensitivities
to several important antiviral nucleotides (23-26). The RT of FIV also has low
fidelity, similar to that of HIV-1 (Garvey et al., unpublished observations).
These features make FIV an attractive model to study mutation frequency
and how it is affected by antiviral drugs or by mutations conferring drug-
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resistance. The FIV model is also highly relevant to HIV. For these studies, we
developed a host-range system that allows measurement of mutation
frequencies in a manner analogous to classic genetic studies with bacteriophage
systems (27). Using this system we can evaluate the effects of antiviral drugs on
the mutation frequency of a lentivirus. We have presented a preliminary report
that the most widely used anti-HIV-1 drug, AZT, increases the mutation
frequency of FIV (28). We report here the details of the FIV host-range system
and the effects of antiviral nucleosides on the mutation frequency of FIV.
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M ATERIALS AND METHODS

Chemicals
5-bromo-2’-deoxyuridine (BUdR) and 2’,3’-dideoxycytidine (ddC) were
purchased form Sigma Chemicals Co. (St. Louis, MO, U.S.A.). AZT was
provided by Phillip A. Furman of Burroughs Wellcome Co. (Research Triangle
Park, NC, U.S.A.). 2',3’-Dideoxyinosine (ddl) was provided by the
Developmental Therapeutics Branch, Division of AIDS, National Institute of
Allergy and Infectious Diseases.

Virus and Ceils

The virus strains used in this study were FIV Petaluma (17,19) and FIV
34TF10, a molecular clone derived from the Petaluma strain (29). Virus was
grown and maintained in Crandell feline kidney (CrFK) cells, which were
obtained from American Type Culture Collection (ATCC) and were cultured
under condition previously described (26). An FIV-resistant variant of CrFK cells,
CrFK-13, is described in Results. When cells reached confluency, they were
passaged by trypsinization, diluted approximately 100-fold, and reseeded in 25cm2 flasks. A single passage includes the period between trypsinization, dilution,
and reseeding the cells, until they become confluent and are ready for
trypsinization again. Cells were passaged approximately once a week. They
were routinely tested with a Gen Probe Mycoplasma detection kit (Gen Prob
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Inc., San Diego, CA, U.S.A.) and were found to be free of any Mycoplasma
contamination.

Focal Infectivity Assay
Infectious FIV was quantified by the focal infectivity assay (FIA) as
previously described (12). Briefly, uninfected CrFK cells were infected with ~2080 focus forming units of FIV. After 5 days, media were removed, and the cells
were fixed with methanol. Infectious foci were detected by reacting with
polyclonal antiserum obtained from FIV-infected, specific-pathogen-free cats
(generously provided by N.C. Pedersen, School of Veterinary Medicine,
University of California, CA, U.S.A.) and then reacted with peroxidaseconjugated anti-cat immunoglobulin (Organon Teknika). The peroxidase stain
was developed with H2O2 and amino-ethyl-carbazole. Infectious foci appeared as
red cells against a background of uninfected (unstained) cells. Plaque
purification of virus from a single foci was performed as previously described
(13).

Determination of Mutation Frequencies
To determine mutation frequencies, cell-free virus was differentially plated
on CrFK-13 (FIV-restrictive) and CrFK (FIV-permissive) cells. For these
experiments, virus grown in the absence or presence of a mutagen or inhibitor
was differentially plated on CrFK-13 cells and FIV-permissive CrFK cells. Before
infection, cells were pretreated with 8 pg/ml diethylaminoethyl dextran for 20 min

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

102

to facilitate adsorption of the virus. The values reported represent the number of
foci formed on CrFK-13 cells divided by the number of foci formed on FIVpermissive CrFK cells, as determined by FIA.
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RESULTS
Development of the Host-Range System
The system we developed uses a strain of Crandell feline kidney (CrFK)
cells that is resistant to infection by wild-type FIV Petaluma or the molecular
clone, FIV 34TF10. As described herein, these cells are used to measure the
proportion of host-range mutant in a population of virus. The FIV-resistant cells
were isolated after we observed that with prolonged passage of FIV-permissive
CrFK cells, we obtained cells that were highly restrictive to FIV infection. Wildtype FIV Petaluma infected these restrictive cells ~1,000 times less efficiently
than permissive CrFK cells, as determined by FIA. As shown in Fig. 1, the
susceptibility of CrFK cells to infection with FIV decreased dramatically as a
function of passage number. We are not certain of the reason for the change in
the cells, but it is presumably due to different growth conditions. ATCC had
grown the CrFK cells in minimum essential medium (Delbecco’s MEM)
supplemented with 10% horse serum, which is different from the medium (L & M
medium supplemented with 10% fetal bovine serum) (26) that is optimal for FIV
replication.
Because the population of FIV-restrictive CrFK cells was expected to be a
heterogeneous mixture, we isolated 19 single-cell clones from this population.
The susceptibilities of these clones to FIV infection are shown in Table 1.
Several of the clones were highly resistant to FIV, whereas others, such as
CrFK-3, were less restrictive, confirming that the original population was a
heterogeneous mixture. We chose one of the clonal isolates, CrFK-13, as a
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highly restrictive host cell for further characterization. This choice was made
based upon the ability to detect a few (potentially mutant) foci of FIV with these
cells.
From these early studies, it was determined that wild-type FIV Petaluma
infected CrFK-13 cells, 1.4±0.4 x 10‘3, as efficiently as permissive CrFK cells.
FIV-permissive CrFK cells are CrFK cells that have been passaged four or fewer
times after they were obtained from ATCC. Experiments were performed to
determine whether the occasional foci observed upon infection of CrFK-13 by
FIV were host-range mutants that were present in the swarm population of the
virus, rather than simply wild-type virus able to form foci owing to leakiness. We
plaque-purified several potential mutants by isolating single foci of FIV Petaluma
on CrFK-13 cells. The resulting host-range (HR) mutants remained infectious to
the FIV-permissive CrFK cells and also infected CrFK-13 cells with much higher
efficiency that the potential wild-type FIV (Table 2).
In order to ascertain whether these viruses are truly mutants, we
assessed their phenotypic stability by passing one of the HR mutants, HR-3,
back into the FIV-permissive CrFK cells.

This was done to test the possibility

that HR mutants were the result of a biochemical adaptation rather than a stable
phenotype. When HR-3 was passaged back into the FIV-permissive cells,
progeny virus retained the ability to infect CrFK-13 cells 100 fold more efficiently
that wild-type FIV (data not shown). This finding confirmed the phenotypic
stability of HR-3. These data suggest that the CrFK/CrFK-13 HR system could
be useful for studies to evaluate the mutation frequency of FIV.
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With this assay, HR mutants are detectable in a normal population at a
frequency of 0.14%. However, the actual mutation frequency is somewhat
higher when corrected for efficiency of plating of HR mutants on CrFK-13 cells
(Table 2). Based upon the six HR mutants we have analyzed, the average
plating efficiencies for HR mutants range from 2.7-18%. This efficiency results in
an actual mutation frequency somewhere between 0.8 and 5.6%. It is apparent
that these variants represent a substantial fraction of the swarm population, but
are at a significant disadvantage relative to wild-type FIV.
To test this system, we examine the effects of a known mutagen, BUdR
(30), to determine whether it increases the frequency of HR mutant in a
population. As shown in Fig. 2A, passage of wild-type FIV Petaluma in the
presence of BUdR increased the mutation frequency in a dose-dependent
manner, up to a level where cytotoxicity was observed (>0.7-1.0 jiM). This
finding confirms that our system can detect an increase in the mutation
frequency due to replication of the virus in the presence of a known mutagen.
The maximum increase in mutation frequency that we observed with BUdR is
only 2.5- to three-fold. We believe that the extremely high basal mutation rate of
FIV limits the extent of mutagenesis and that higher mutation rates would result
in too many lethal mutations. We believe that the apparent leveling off of the
mutation frequency seen with higher concentrations of BUdR is not due to an
actual leveling off of the mutation frequency, but rather to a limitation in the
sensitivity of the system when the inhibition of virus replication results in titers too
low for accurate scoring of mutants.
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The experiments with BUdR was also performed with FIV obtained from
the molecular clone FIV 34TF10, which represents a more homogenous
population than the swarm population of FIV Petaluma. The mutation frequency
of FIV 34TF10 also increased in the presence of BUdR. This result indicates
that replication in the presence of the mutagen increased the mutation frequency
of the virus regardless of the degree of heterogeneity of the starting population.

Effects of Antiviral Drugs on the Mutation
Frequency of FIV
With the confirmation that our HR system is able to detect an increase in the
mutation frequency due to the presence of a mutagen, we evaluated the effects
of antiviral drugs upon the mutation frequency of FIV. As shown in Fig. 2B, when
wild-type FIV Petaluma replicated in the presence of AZT, a dose-dependent
increase of the mutation frequency was detected. Similar results were obtained
in experiments with the molecular clone FIV 34TF10. We also evaluated two
other antiviral nucleosides approved for AIDS chemotherapy. Replication of
wild-type FIV Petaluma in the presence of ddl and ddC resulted in little or no
detectable increase in the mutation frequency (fig 2C and 2D, respectively).

DISCUSSION
AZT is negative in the Ames test, only weakly mutagenic in assays with cultured
mammalian cells, and weakly carcinogenic in rodents (31). However, the
mutagenicity of AZT to FIV cannot be considered weak; AZT enhances the
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mutation frequency of FIV by nearly as much as BUdR, a well-characterized
mutagen. This ability of AZT to enhance the mutation frequency of a lentivirus
may have important implications for AIDS chemotherapy, but it is not clear
whether this enhanced mutagenesis will be beneficial or detrimental. If AZT
produces an increased frequency of lethal mutations among the population of
virus escaping drug, it may contribute to antiviral activity. However, it is likely
that an enhanced mutation rate will also contribute to mutations involved in
antigenic variation, evasion of the immune system, and changes in cell tropism.
If the rate of pathogenesis is in fact dependent upon accumulation of multiple
mutations, then AZT therapy may alter the rate of pathogenesis.
The genetic system we have developed quantitates the proportion of virus
with a particular phenotype, in this case the number of HR mutants present
within a population of viable virus. The baseline frequencies we report are not
mutation rates, but rather the proportion of mutants in an equilibrium population.
The mutation frequency of a retrovirus is dependent upon forward mutation rate,
reverse mutation rate, replication rate, and number of replication cycles (32. 33).
AZT lowers the replication rate and number of replication cycles, and so these
two factors are not important to the AZT-induced enhancement of mutation
frequency. The reverse mutation rate will be considerably lower than the forward
rate, owing to the fact that HR mutants are a minor fraction of the population;
thus it will contribute little. Therefore, the AZT-induced increase in mutation
frequency is most likely due to an enhancement o f the mutation rate by AZT.
We cannot be certain that the other drugs tested, ddl and ddC, are not
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mutagenic, since it is possible that they exert and effect that is below our level of
detection. Nevertheless, it is clear that AZT is much more mutagenic than these
other antivirals to FIV.
The mutagenicity of AZT was at subinhibitory concentrations of AZT. We
believe there would be even more mutagenicity at higher levels. We also believe
that studies performed at these low drug levels are relevant to the clinical use of
AZT. It is clear that patients are exposed to concentrations that inhibit HIV-1
replication only partly, or at subtherapeutic levels, during periods of therapy. The
dose of AZT used in humans is three- to six-fold lower than was suggested from
early pharmacokinetic studies, and trough levels of AZT are considerably below
the minimum inhibitory concentration of the drug (34,35). Virus that is
replicating, albeit at a reduced rate, during these periods of exposure to low AZT
concentrations may have an enhance mutation rate.
We do not know the mechanism of this AZT-induced mutagenesis. AZT
has been shown to cause alterations in levels of DNA precursors (dNTPs)
(36,37), presumably due to effects of AZTMP on thymidylate kinase (38). It is
well established that dNTP pool imbalances can enhance mutation rates of
cultured cells (39). It is possible that the reverse transcriptase-catalyzed
replication of retroviruses is particularly sensitive to pool imbalances owing to
the lack of an associated exonuclease to carry out an editing function. It is also
possible that the mutagenicity of AZT results from an effect of AZTTP directly on
RT or is an indirect result of the incorporation of this analog into DNA (and
attempted repair). It is also possible that the apparent mutagenic effects of
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BUdR and AZT are due to selection of HR variants rather than mutagenic
effects. However, we believe it is unlikely in view of the well-known mutagenic
properties of BUdR (30). Moreover, AZT-resistant mutants of FIV do not display
an HR phenotype (data not shown).
The HR system we have developed with FIV is conceptually similar to
phage genetic systems, and we believe that it will be important for studies on
variability and fidelity of replication of a lentivirus. Our initial goal in development
of this system was to obtain a genetic marker independent of the reverse
transcriptase-encoding region of the pol gene. We would like to use this system
to identify pol mutants of FIV that have mutator or antimutator phenotypes. We
have already determined that the FIV RT has a low fidelity, similar to that
reported for the HIV-1 RT (Garvey et al., unpublished observations). We also
have a large number of FIV variants containing pol mutations that were selected
as drug-resistant mutants. The systems we have developed will be used to
determine how alterations of fidelity at the enzyme level correlate with mutation
rates during virus replication.
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FIGURE LEGENDS
FIG. 1. Effects of passage of CrFK cells on susceptibility to FIV infection.
Susceptibility of these cells to infection by FIV was determined by FIA. The
same cell-free virus stock was used to infect all of the preparations of CrFK cells.
The infectivities of FIV Petaluma (▲) and 34TF10 (■) were determined as a
function of increasing passage number. Each value represents an average of at
least four determinations.

FIG. 2. Mutation frequency of FIV grown in the presence of a mutagen or
antiviral drugs. CrFK cells were infected with wild-type FIV Petaluma (▲) or FIV
34TF10 (■) in the presence of indicated concentrations of BUdR (A), AZT (B),
ddl (C), and ddC (D). Mutation frequencies in the absence of drugs were
0.0050±0.0003 for FIV Petaluma and 0.0057±0.0003 for FIV 34TF10. The
mutation frequency value seen here for FIV Petaluma is slightly different from
what is seen in Table 1, owing t the fact that these assays were performed using
a different stock of virus. It has been found that different stocks of virus have
slightly different background levels of HR mutants. Each value represents two or
more experiments with at least four determinations per experiment. The error
bars represent the standard error of the mean.
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TABLE 1. PLATING E F F IC IE N C Y O F W ILD-TYPE FIV O N S IN G L E -C E L L C L O N E S
O F FIV-RESTRICTIVE C rF K C E L L S '
C rF K C L O N E 11
2
3
4
5
6
7
9
10
11
12
13 §
14
15
16
17
18
19
20

•

PLA TIN G E F F IC IE N C Y *
7 . 8 x 1 O'3
< 4 . 4 x 1 O'4
4 .3 x 1 0 '2
2 . 6 x 1 O'3
2 .6 x 1 0 '3
< 4 . 4 x lO '4
8 . 7 x 1 O'3
2 .1 x l O ' 3
< 4 . 4 x 1 0 '4
< 4 . 4 x 1 O'4
< 4 . 4 x 1 O’4
1 .4 ± 0 .4 x 1 0
< 4 . 4 x 1 O'4
4 .4 x 1 0 ‘4
< 4 . 4 x 10*4
1 . 4 x 1 0 '2
< 4 . 4 x 1 O'4
1 .7 x 1 0 '3
1 . 9 x 1 O'2

' This t a b l e re p re s e n ts t h e in itial s c r e e n in g o f a ll o f t h e c lo n e s ,
l i m i t e d d ilu tio n s o f a p o p u la t io n o f F IV -re s tric tiv e C rF K c e lls w e r e u s e d
t o is o la te s in g le c e ll c lo n e s .
*B y d iffe re n tia lly p la tin g c e ll- f r e e FIV P e t a lu m a o n t h e re s tric tiv e c lo n e s
a n d o n t h e F IV -p e rm is s iv e C rF K c e lls , p la tin g e f f ic ie n c y o f t h e virus w a s
o b t a in e d b y d iv id in g th e n u m b e r o f fo c i d e t e c t e d o n re s tric tiv e c e lls b y
t h e n u m b e r o f fo c i d e t e c t e d o n t h e F IV -p e rm is s iv e C rF K c e lls .
§C lo n e C rF K -1 3 w a s s e le c t e d fo r fu rth e r e x p e r im e n ts a n d u s e d fo r th e
d e v e lo p m e n t o f t h e h o s t r a n g e s y s te m . T h e s ta n d a r d e rro r o f t h e m e a n
fro m m o r e th a n fiv e e x p e r im e n ts is in d ic a t e d ._ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
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TABLE 2 . RELATIVE P LA T IN G E F F IC IE N C IE S O F H O S T -R A N G E (HR) MUTANTS
Virus'
P e t a lu m a

PLAT. E F F IC .*
0 .0 0 1 4 ± 0 .0 0 0 4 *

F O L D IN C R E A S E 5
IX

HR1

0 . 0 3 9 ± 0 .0 0 7

28X

HR2

0 .0 2 7 ± 0 .0 1 0

19X

HR3

0 .1 8 ± 0 .0 3 4

129X

HR4

0 .0 7 2 ± 0 .0 1 4

51X

HR5

0 . 1 6 ± 0 .0 5 9

114X

HR6

0 .0 4 2 ± 0 .0 0 8

30X

* E a c h p o te n tia l m u t a n t w a s is o la te d fr o m a s in g le fo c u s f o r m e d o n
C rF K -1 3 c e lls .
* P la tin g e ffic ie n c ie s o f t h e HR m u ta n ts w e r e d e t e r m in e d b y d iv id in g th e
n u m b e r o f fo c i s e e n o n C R F K -1 3 c e lls b y t h e n u m b e r o f fo c i s e e n o n
F IV -p e rm is s iv e C rF K c e lls . E a c h v a lu e re p re s e n ts t h e results o f tw o o r
m o r e e x p e r im e n ts w ith a t le a s t fo u r d e te r m in a tio n s p e r e x p e r im e n t.
* S ta n d a r d e rro r o f t h e m e a n .
§ In c r e a s e d e f f ic ie n c y o f in fe c tio n o f HR m u ta n ts o n F IV -re s tric tiv e c e lls
a s c o m p a r e d to t h e c o n tr o l, FIV P e ta lu m a .
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Chapter 7
Conclusions
By utilizing the host range system of the FIV model, it has been
determined that AZT is mutagenic to FIV. The mutagenicity of AZT to FIV is
nearly as high as the well-characterized mutagen, BUdR. However, two other
RT inhibitors, ddl and ddC, tested negative for mutagenicity to FIV with this
system. The mutagenicity of AZT could have major implications for AIDS
chemotherapy, although it is not clear whether an increase in the mutation
frequency of the virus would be beneficial or detrimental. If there was an
increase in the frequency of lethal mutations during replication, it may contribute
to the antiviral activity of the drug. However, it is likely that the enhanced
mutation rate would contribute to mutations involved in genetic variation, evasion
of the immune system, and changes in cell tropism. If pathogenesis is
dependent upon accumulation of multiple mutations, AZT therapy could
potentially alter the rate of pathogenesis.
The FIV host range system will be important for studying the variability
and fidelity of the replication of the lentivirus. It can be utilized to identify pol
mutations with antimutator and mutator phenotypes. There are a number of drug
resistant mutants with known pol mutations available and can be evaluated for
these phenotypes. This system can also be used to determine how alterations of
fidelity at the enzyme level correlate with the mutation rates during viral
replication. In addition, this system can also be used to evaluate the mutagenic
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effect of new antiviral drugs being developed (or drug combination) for AIDS
chemotherapy.
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